Why would Pope PR a heavily reduced sale just to get hammered by short sellers and bad press? I guess We will all see what the sale price was during the next quarterly call.
Lets talk about the $5 million in stock sale by Pope and the CFO. Why sell more than half of you stock if Alf is poised to be a competitor to ISRG? Also, did you read the Motley fool article? Seems to be right on the money.
What do you think is healthy in regards to sales? Trcx has a massive monthly cash burn and lets not forget the 17 million in debt... Best chance for TRXC is is a partnership going forward with someone other than a tray supplier.
read this:
The Senhance is a relatively old surgical bot. It has just been approved in the US, but got European approval back in 2011. Compare that to Intuitive Surgical’s (ISRG) Da Vinci X system just got approved earlier this year in the US and Europe. However, the Senhance hasn’t been very popular in Europe. As stated in this article, TransEnterix has been marketing the Senhance since late 2015 when it took ownership of the robot, and has only sold three Senhance robots over the entire continent. We wondered why this surgical robot has been so unpopular among European surgeons.
News 
Market Data 
Discover 
AI
